Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
Celgene
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Fate Therapeutics
Augusta University